Recent Activity
-
Jan 24
I recently heard a physician quote a paper from JACC to justify pursuing revascularization in an asymptomatic patient who was scheduled for major vasc... -
Jan 24
The American Heart Association (AHA) is projecting that the cost to treat heart disease in the U.S. will triple by 2030, from $273 billion today to $8... -
Jan 21 The Heart Rhythm Society (HRS) has informed its members that it is “aware of an ongoing U.S. Department of Justice (DOJ) civil investigation of Implan...
-
Jan 21
According to a recently published opinion piece in a British cardiology journal, enthusiasm for the transradial approach over the femoral approach in ... -
Jan 20 A key detail has now emerged about the problems encountered with vorapaxar, Merck's thrombin receptor antagonist that suffered a large setback last we...
-
Jan 19 The PROSPECT trial provides some interesting insights about the mechanisms of thrombotic coronary artery disease, but how, if at all, should it change...
-
Jan 19 A Cochrane Review raises troubling questions about the evidence base supporting the use of statins for primary prevention. The Cochrane reviewers anal...
-
Jan 19 A study published in the Lancet lends support to a new form of CPR that uses a combination of two devices to provide three times more blood flow to th...
-
Jan 14 The FDA has released a safety communication about severe liver injury associated with Multaq (dronedarone). The FDA said that information about the ri...
-
Jan 14 In the ACCELERATE (Aliskiren and the calcium channel blocker amlopdipine combination as an initial treatment strategy for hypertension control) trial,...
-
Jan 13 Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is b...
-
Jan 12 The PARTNER trial of transcatheter aortic valve implantation (TAVI) for severe aortic stenosis was among the hottest cardiology stories of 2010. Now ...
-
Jan 12 Two papers published in the New England Journal of Medicine shed new light on the important but often mysterious role of HDL cholesterol in cardiovasc...
-
Jan 12 Clyde Yancy, a former president of the AHA, is leaving Baylor University to succeed Robert Bonow as the chief of the division of cardiology at the Nor...
-
Jan 12 A large network meta-analysis has found “little evidence” to suggest that any of the commonly used NSAIDs or COX 2 inhibitors are safe in terms of car...
-
Jan 11 The Swedish Heart Failure Registry followed more than 5,000 patients treated with the angiotensin II receptor blockers (ARBs) candesartan or losartan ...
-
Jan 11 Have questions about the new stent that just received CE Mark approval in Europe? Here's a reality checklist. 1. What’s it called? The bioresorbable v...
-
Jan 11 Dear Colleagues, We launched CardioExchange in an effort to build a non-partisan venue for the exchange of information and views about the world of ca...
-
Jan 10 In this journal club, I compare the published data from an original trial with the authors’ conclusions in a substudy from that trial. Often, a substu...
-
Jan 10 Abbott announced today that it had received CE Mark approval for Absorb, its bioresorbable vascular scaffold (BVS) device. The device props a narrowed...
-
Viewing item 1,221 to 1,240 (of 1,793 items)
Sandeep Goyal shares his experience at the Heart Rhythm Society meeting in Denver: 
